Sword only depletes high 4-1bb+ cells, Dr. V mentioned that in presentation. You can check the poster on 836 to see this There is not many activated effectors in MSS CRC anyway unlike NSCLC. CD58 KO also raise the threshold for sword to deplete most immune cells activated.
Recent FATE News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 12:34:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 12:32:07 PM
- Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:00:36 PM
- Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 • GlobeNewswire Inc. • 05/05/2026 12:30:00 PM
- Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases • GlobeNewswire Inc. • 05/04/2026 01:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2026 08:05:00 PM
- Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting • GlobeNewswire Inc. • 04/30/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:09:40 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:08:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:03:55 PM
- Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annua • GlobeNewswire Inc. • 04/16/2026 01:00:00 PM
- Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences • GlobeNewswire Inc. • 04/09/2026 01:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed • GlobeNewswire Inc. • 03/18/2026 03:30:00 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/04/2026 09:05:00 PM
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 09:05:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (Canada) • 03/03/2026 03:02:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (US) • 03/03/2026 03:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:07:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 02:04:07 PM
- Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates • GlobeNewswire Inc. • 02/26/2026 02:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets • PR Newswire (Canada) • 01/26/2026 03:16:00 PM
